Lund University
Clinical Memory Research Unit
In 2014, I obtained my MD at the University of Perugia, Italy. Here, I worked at the Memory Clinic led by Professor Lucilla Parnetti. My research focus was on diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers in memory impairment and dementia due to Alzheimer’s disease (AD). In 2019, I completed my PhD in Kaj Blennow’s lab at the University of Gothenburg, Sweden. Here I studied tau protein and its role in the pathogenesis and as a biomarker of AD and tauopathies. During the PhD, I developed immunoassays targeting several different tau fragments in CSF and brain extracts. The developed assays were used in several clinical studies, where I also assessed the relationship between tau fragments and findings at tau PET. Since 2020, I work both clinically as a Psychiatry resident at Skåne University Hospital, Malmö, and as a postdoctoral researcher in Oskar Hansson’s lab at the Clinical Memory Research Unit, Lund University. My focus is on blood biomarkers for AD within the Swedish BioFINDER study.

Presenter of 1 Presentation

APOE GENOTYPE, AGE AND SEX AFFECT LONGITUDINAL CHANGE OF CEREBROSPINAL FLUID BIOMARKERS: FINDINGS FROM THE SWEDISH BIOFINDER COHORT

Session Type
SYMPOSIUM
Date
Sun, 20.03.2022
Session Time
11:35 AM - 01:35 PM
Room
ONSITE: 113
Lecture Time
11:35 AM - 11:50 AM

Abstract

Aims

Aims

In this study we assessed the effects of APOE genotype, age, and sex on the longitudinal change of CSF biomarkers of Alzheimer’s disease (p-tau181), astrocytosis (YKL-40, GFAP) and microglial activation (sTREM2) in the longitudinal Swedish BioFINDER cohort.

Methods

Methods

CSF was collected at baseline and 2-, 4-, 6-, 8- and 10-years’ follow-up from cognitively unimpaired (CU, n=801) or MCI (n=265) patients. Aβ status was defined based on the CSF Aβ42/40 ratio in CSF. Biomarkers were measured with NeuroToolKit (Roche). Reliability of change index (RCI) was calculated in Ab negative CU to define “stable” (slope of change over time=+/-RCI) and “increasers” (slope>RCI) groups in the cohort. Logistic regression was used to assess effects of APOE, age and sex on the “stable” vs. “increaser” outcome.

Results

Results

Increases in CSF p-tau181 over time due to APOE genotype are fully mediated by Aβ+ status (p<0.0001, OR 7.6). GFAP and sTREM2 increased less in women than in men over time, independently of Aβ status (GFAP: p=0.01, OR 0.6; sTREM2: p=0.003, OR 0.4). Increase in YKL-40 over time was affected by age, independently of Aβ status (p=0.02, OR 1.1).

Conclusions

Conclusions

Aβ status, age, and sex affect longitudinal change of CSF biomarkers. The present findings warrant for adjustment for these variables in longitudinal studies.

Hide